Download presentation
Presentation is loading. Please wait.
1
<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions
Public Health Genomics 2012;15:1–10 - DOI: / Fig. 1. Rate of HER2 testing at KPNW from 1998 to The solid lines correspond to patients diagnosed with invasive breast cancer with Medicare/Medicaid insurance (diamonds) or with other insurance (circles), and the dashed lines correspond to patients diagnosed with ductal carcinoma in situ or noninvasive breast cancer. © 2011 S. Karger AG, Basel - CC BY-NC 3.0
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.